Clinical Trials on Granuloma, Plasma Cell in China

Total 4875 results

Yao Liu

Recruiting

Efficacy and Safety of PEG-rhG-CSF Injection for Neutrophil Reconstitution Following AHSCT in Lymphoma/Multiple Myeloma

Lymphoma | Multiple Myeloma

China
Shanghai Changzheng Hospital
RenJi Hospital; Huashan Hospital; Shanghai 6th People's Hospital; Huadong Hospital

Recruiting

A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia (CZ-WM01)

Waldenström's Macroglobulinemia

China
Keymed Biosciences Co.Ltd

Recruiting

Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma

Lymphoma | Multiple Myeloma

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia

Waldenström Macroglobulinemia

China
Weijun Fu
Nanjing Legend Biotech Co.

Active, not recruiting

A Single-center Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of a BCMA-targeted Universal LCAR-BCX Cells in Patients With Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

China
Institute of Hematology & Blood Diseases Hospital

Unknown

Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia (BDH-WM03)

Waldenström Macroglobulinemia

China
Beijing Chao Yang Hospital
Peking University People's Hospital

Unknown

CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma

Extramedullary Plasmacytoma

China
Shenzhen Pregene Biopharma Co., Ltd.

Recruiting

Clinical Study of the Safety and Efficacy of BCMA CAR-NK

Multiple Myeloma | Immunotherapy

China
Guangdong Provincial People's Hospital

Recruiting

Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis

Immunoglobulin Light-Chain Amyloidosis

China
Wuhan Union Hospital, China

Recruiting

The Prognostic Value of CPCs Quantified by Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical Trial

Multiple Myeloma

China
Shanghai Henlius Biotech

Completed

A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects

Multiple Myeloma

China
GlaxoSmithKline

Completed

A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Multiple Myeloma

China
Shenzhen Geno-Immune Medical Institute

Unknown

Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma

Multiple Myeloma

China
Shanxi Bethune Hospital

Recruiting

Clinical Study of Reduced-dose Pomalidomide and Cyclophosphamide Combined With Dexamethasone in the Treatment of Patients With Debilitating RRMM

Multiple Myeloma in Relapse

China
Shenzhen Geno-Immune Medical Institute
The Second Affiliated Hospital of Hainan Medical University

Recruiting

Universal CAR-T Cells Targeting Multiple Myeloma

Multiple Myeloma in Remission

China
Henan Cancer Hospital
The Pregene (ShenZhen) Biotechnology Company, Ltd.

Unknown

BCMA-CAR-T in Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Myeloma

China
The First Affiliated Hospital of Soochow University

Unknown

PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia

Treatment

China
Institute of Hematology & Blood Diseases Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd.

Not yet recruiting

YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
Zhujiang Hospital
The Third Affiliated Hospital of Southern Medical University; Sun Yat-Sen Memorial... and other collaborators

Terminated

CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma (MM)

Relapsed/Refractory Multiple Myeloma(MM)

China
Guangzhou Bio-gene Technology Co., Ltd

Recruiting

Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Multiple Myeloma

Multiple Myeloma in Relapse

China
Second Affiliated Hospital of Soochow University
The Affiliated Hospital of Xuzhou Medical University

Recruiting

Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

China
Zhejiang University
Yake Biotechnology Ltd.

Not yet recruiting

A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy

Relapse Multiple Myeloma

China
The First Affiliated Hospital of Soochow University

Recruiting

Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT

Safety and Efficacy

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Sir Run Run Shaw Hospital

Completed

Clinical Study of T Cell Infusion Targeting BCMA Chimeric Antigen Receptor

Multiple Myeloma

China
Shenzhen Second People's Hospital

Unknown

Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma

Multiple Myeloma in Relapse

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Yanda Ludaopei Hospital; Beijing Lu Daopei Hospital

Unknown

Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
Jiangsu Simcere Pharmaceutical Co., Ltd.
Shanghai Xianxiang Medical Technology Co., Ltd.

Recruiting

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
Beijing Mabworks Biotech Co., Ltd.

Recruiting

A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.

Relapsed or Refractory Multiple Myeloma

China
Institute of Hematology & Blood Diseases Hospital
MethylGene Tech Co., Ltd. China

Recruiting

ctDNA Methylation Sequencing for Myeloma

Multiple Myeloma

China
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....

Recruiting

Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM

Relapsed or Refractory Multiple Myeloma

China
Xinhua Hospital, Shanghai Jiao Tong University...
CARsgen Therapeutics Co., Ltd.

Active, not recruiting

Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma

Refractory or Relapsed Multiple Myeloma

China
Fuzhou General Hospital

Unknown

The Plasma Diafiltration Therapy of Hepatic Failure

Hepatic Failure | Plasma Exchange

China
Changzhou No.2 People's Hospital

Not yet recruiting

An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma

Multiple Myeloma

China
Jinling Hospital, China

Recruiting

Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation

Newly Diagnosed Multiple Myeloma

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Second Affiliated Hospital of Soochow University

Recruiting

UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

China
He Huang
Yake Biotechnology Ltd.

Recruiting

A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

Relapse/Refractory Multiple Myeloma

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

the Safety and Efficacy of SENL103 Autologous T Cell Injection

Multiple Myeloma

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma

Multiple Myeloma | New Diagnosis Tumor

China
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Not yet recruiting

Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

China
The First Affiliated Hospital of Soochow University

Withdrawn

An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201 Infusion in Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

China
The First Affiliated Hospital of Soochow University
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y001#

Relapsed/Refractory Multiple Myeloma

China
The First Hospital of Jilin University

Unknown

Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone in the Treatment of the First Relapsed Multiple Myeloma

Multiple Myeloma in Relapse

China
Sun Yat-sen University

Withdrawn

Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Relapse/Refractory Multiple Myeloma

China
Sun Yat-sen University

Unknown

CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma

Multiple Myeloma

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities

Multiple Myeloma

China
Shenzhen University General Hospital

Recruiting

B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Relapse Multiple Myeloma

China
Second Affiliated Hospital, School of Medicine,...
Carbiogene Therapeutics Co. Ltd.

Recruiting

Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
Zhejiang University
Yake Biotechnology Ltd.

Not yet recruiting

A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

Refractory Multiple Myeloma | Relapse Multiple Myeloma

China
First Affiliated Hospital of Fujian Medical University

Recruiting

Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases

Lymphoma | Leukemia | Multiple Myeloma

China
First Affiliated Hospital of Zhejiang University
CARsgen Therapeutics Co., Ltd.

Active, not recruiting

Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma

Refractory or Relapsed Multiple Myeloma

China

Clinical Trials on Granuloma, Plasma Cell in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations